Mechanism of action of rapamycin (Sirolimus, Rapamune).
Molnar-Kimber
K L
KL
Inflammatory Disease Division, Wyeth-Ayetn Research, Princeton, New Jersey, USA.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D002352:Carrier Proteins / Q000378:metabolism; D002417:Cattle; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D016207:Cytokines / Q000096:biosynthesis; D004268:DNA-Binding Proteins / Q000378:metabolism; D006360:Heat-Shock Proteins / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D051379:Mice; D011090:Polyenes / Q000494:pharmacology*; D020123:Sirolimus; D013601:T-Lymphocytes / Q000276:immunology*; D022021:Tacrolimus Binding Proteins; D014407:Tumor Cells, Cultured
D000903:Antibiotics, Antineoplastic; D002352:Carrier Proteins; D016207:Cytokines; D004268:DNA-Binding Proteins; D006360:Heat-Shock Proteins; D007166:Immunosuppressive Agents; D011090:Polyenes; D022021:Tacrolimus Binding Proteins; D020123:Sirolimus